MARKET

ARWR

ARWR

Arrowhead Pharma
NASDAQ
69.62
-0.54
-0.77%
After Hours: 69.62 0 0.00% 19:59 12/29 EST
OPEN
69.39
PREV CLOSE
70.16
HIGH
69.69
LOW
68.00
VOLUME
896.73K
TURNOVER
--
52 WEEK HIGH
72.36
52 WEEK LOW
9.57
MARKET CAP
9.46B
P/E (TTM)
-5706.5574
1D
5D
1M
3M
1Y
5Y
1D
My Market Outlook For 2026: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares
Seeking Alpha · 14h ago
iShares Core S&P Small-Cap ETF Experiences Big Outflow
NASDAQ · 14h ago
Weekly Report: what happened at ARWR last week (1222-1226)?
Weekly Report · 20h ago
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After FDA Breakthrough Status for Plozasiran and Redemplo Launch
Simply Wall St · 5d ago
Arrowhead Pharmaceuticals CFO William D. Waddill Reports Sale of Common Shares
Reuters · 6d ago
Arrowhead Pharmaceuticals Director Victoria Vakiener Reports Sale of Common Shares
Reuters · 6d ago
Arrowhead Pharmaceuticals CEO Christopher Richard Anzalone Reports Sale of Common Shares
Reuters · 6d ago
Arrowhead Pharmaceuticals Chief Medical Officer Adeoye Y. Olukotun Reports Sale of Common Shares
Reuters · 6d ago
More
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.

Webull offers Arrowhead Pharmaceuticals Inc stock information, including NASDAQ: ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.